BR112023005795A2 - Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer - Google Patents

Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer

Info

Publication number
BR112023005795A2
BR112023005795A2 BR112023005795A BR112023005795A BR112023005795A2 BR 112023005795 A2 BR112023005795 A2 BR 112023005795A2 BR 112023005795 A BR112023005795 A BR 112023005795A BR 112023005795 A BR112023005795 A BR 112023005795A BR 112023005795 A2 BR112023005795 A2 BR 112023005795A2
Authority
BR
Brazil
Prior art keywords
treatment
recombinant fusion
composition
cancer
kit
Prior art date
Application number
BR112023005795A
Other languages
English (en)
Inventor
Hoon Cha Sang
Original Assignee
Aprilbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co Ltd filed Critical Aprilbio Co Ltd
Publication of BR112023005795A2 publication Critical patent/BR112023005795A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTEÍNA DE FUSÃO RECOMBINANTE, MOLÉCULA DE ÁCIDO NUCLEICO, VETOR DE EXPRESSÃO, CÉLULA, COMPOSIÇÃO, COMPOSIÇÃO FARMACÊUTICA, KIT, MÉTODO PARA TRATAR UMA DOENÇA IMUNE E MÉTODO PARA TRATAR CÂNCER. São fornecidas no presente pedido proteínas de fusão recombinantes que compreendem uma proteína de ligação à interleucina-18 e um fragmento de ligação ao antígeno contra albumina de soro e usos das mesmas. As proteínas de fusão recombinantes têm um ciclo de administração melhorado devido a um aumento na meia-vida no corpo. Além disso, as proteínas de fusão recombinantes têm baixa imunogenicidade e não causam efeitos colaterais in vivo e, portanto, podem ser efetivamente usadas para o tratamento de vários tipos de câncer e doenças e condições imunes.
BR112023005795A 2020-09-29 2021-09-29 Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer BR112023005795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200127395A KR20220044057A (ko) 2020-09-29 2020-09-29 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
PCT/IB2021/058964 WO2022070112A1 (en) 2020-09-29 2021-09-29 Recombinant fusion proteins comprising interleukin- 18-binding protein and antigen binding fragment to serum albumin, and compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112023005795A2 true BR112023005795A2 (pt) 2023-04-25

Family

ID=80949882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005795A BR112023005795A2 (pt) 2020-09-29 2021-09-29 Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer

Country Status (9)

Country Link
US (1) US20230357340A1 (pt)
EP (1) EP4222162A1 (pt)
JP (1) JP2023543461A (pt)
KR (2) KR20220044057A (pt)
CN (1) CN117015553A (pt)
AU (1) AU2021352174A1 (pt)
BR (1) BR112023005795A2 (pt)
CA (1) CA3193862A1 (pt)
WO (1) WO2022070112A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240055222A (ko) * 2022-10-19 2024-04-29 주식회사 에이프릴바이오 인터루킨-2 변이 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
UA117493C2 (uk) * 2013-08-30 2018-08-10 Апрілбіо Ко., Лтд Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
EP3041864B1 (en) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases

Also Published As

Publication number Publication date
KR20230093271A (ko) 2023-06-27
CN117015553A (zh) 2023-11-07
EP4222162A1 (en) 2023-08-09
KR20220044057A (ko) 2022-04-06
CA3193862A1 (en) 2022-04-07
AU2021352174A1 (en) 2023-05-04
JP2023543461A (ja) 2023-10-16
WO2022070112A1 (en) 2022-04-07
US20230357340A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US20220047675A1 (en) Pharmaceutical compositions comprising peptide variants and methods of use thereof
Akash et al. Development of therapeutic proteins: advances and challenges
CN109152818B (zh) 具有降低的抗原性的聚合物结合物及其使用方法
Mantile et al. Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin.
BR112018073909A2 (pt) proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
RU2015136440A (ru) Композиции и способы применения для лечения метаболических расстройств
BR112013030432A2 (pt) método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
BR0007840A (pt) Proteìnas de fusão her-2/neu
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
Scaramuzza et al. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization
BR112023005795A2 (pt) Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer
RU2010136029A (ru) Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты
WO2008058547A2 (en) Alpha-lactalbumin composition
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
US11324811B2 (en) Optimization of enzyme replacement therapy for treatment of homocystinuria
BR9814370A (pt) Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.
BRPI0411510A (pt) proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno
US11135299B2 (en) Chemoselective modification of a carrier protein with a strained alkyne-labeled cargo agent
US20050036984A1 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
PT1807518E (pt) Alfa-fetoproteína recombinante, método e meios para a sua preparação, composições baseadas na mesma e sua utilização
Mistarz et al. Expression, purification and characterization of GMZ2’. 10C, a complex disulphide-bonded fusion protein vaccine candidate against the asexual and sexual life-stages of the malaria-causing plasmodium falciparum parasite
CO2023004265A2 (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
BR0211091A (pt) Métodos para redução de imunogenicidade de polipeptìdeos
Takemoto et al. Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice